[go: up one dir, main page]

ECSP088214A - Formulaciones de acetato de bazedoxifeno que tienen una conversión polimórfica reducida - Google Patents

Formulaciones de acetato de bazedoxifeno que tienen una conversión polimórfica reducida

Info

Publication number
ECSP088214A
ECSP088214A EC2008008214A ECSP088214A ECSP088214A EC SP088214 A ECSP088214 A EC SP088214A EC 2008008214 A EC2008008214 A EC 2008008214A EC SP088214 A ECSP088214 A EC SP088214A EC SP088214 A ECSP088214 A EC SP088214A
Authority
EC
Ecuador
Prior art keywords
polymorphic conversion
acetate formulations
bazedoxifen acetate
reduced
reduced polymorphic
Prior art date
Application number
EC2008008214A
Other languages
English (en)
Inventor
Syed M Shah
Eric C Ehrnsperger
Christopher R Diorio
Kadum A Ali
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37772333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088214(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP088214A publication Critical patent/ECSP088214A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención está dirigida a formulaciones de acetato de bazedoxifeno que tienen una conversión polimórfica reducida, a composiciones que las contienen, a sus preparaciones y sus usos.
EC2008008214A 2005-08-24 2008-02-22 Formulaciones de acetato de bazedoxifeno que tienen una conversión polimórfica reducida ECSP088214A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71076105P 2005-08-24 2005-08-24

Publications (1)

Publication Number Publication Date
ECSP088214A true ECSP088214A (es) 2008-03-26

Family

ID=37772333

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008214A ECSP088214A (es) 2005-08-24 2008-02-22 Formulaciones de acetato de bazedoxifeno que tienen una conversión polimórfica reducida

Country Status (21)

Country Link
US (1) US7771744B2 (es)
EP (1) EP1919456A2 (es)
JP (2) JP2009506053A (es)
KR (2) KR101584674B1 (es)
CN (1) CN101304731B (es)
AR (1) AR056471A1 (es)
AU (1) AU2006283121A1 (es)
BR (1) BRPI0615341A2 (es)
CA (1) CA2620174A1 (es)
CR (1) CR9746A (es)
EC (1) ECSP088214A (es)
GT (1) GT200600383A (es)
IL (2) IL189648A (es)
MX (1) MX2008002484A (es)
NO (1) NO20080991L (es)
PE (1) PE20070425A1 (es)
RU (1) RU2417084C2 (es)
SV (1) SV2008002825A (es)
TW (1) TW200738281A (es)
WO (1) WO2007024961A2 (es)
ZA (1) ZA200801742B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2400227C2 (ru) * 2004-04-08 2010-09-27 Вайет Состав, содержащий твердую дисперсию базедоксифен ацетата
BRPI0615341A2 (pt) * 2005-08-24 2011-05-17 Wyeth Corp composições farmacêuticas contendo acetato de bazedoxifeno, processo para preparação destas e comprimido ou cápsula contendo a referida composição
KR101324898B1 (ko) * 2006-03-31 2013-11-04 루비콘 리서치 피브이티. 엘티디. 구강 붕해 정제
WO2008079342A2 (en) * 2006-12-21 2008-07-03 Mallinckrodt Inc. Composition of and method for preparing orally disintegrating tablets
WO2009102771A1 (en) * 2008-02-11 2009-08-20 Wyeth Methods of converting polymorphic form b of bazedoxifene acetate to polymorphic form a of bazedoxifene acetate
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
AU2011334679B2 (en) * 2010-11-30 2016-12-15 Wista Laboratories Ltd. Formulations comprising methylthioninium chloride
EP2471770A1 (en) 2010-12-28 2012-07-04 Sandoz Ag Method of preparing polymorphic pure form A of bazedoxifene acetate
WO2013182169A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
WO2013182170A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate
CN103877581B (zh) * 2014-03-24 2016-03-02 江苏知原药业有限公司 一种性能优异的乙酸巴多昔芬缓释制剂
WO2018182205A1 (ko) * 2017-03-30 2018-10-04 한미약품 주식회사 바제독시펜 아세테이트를 함유하는 안정화된 약제학적 조성물
KR101940569B1 (ko) * 2017-05-24 2019-01-21 아주대학교산학협력단 바제독시펜 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물
CN112076163B (zh) * 2019-06-14 2023-06-20 四川科伦药物研究院有限公司 一种醋酸巴多昔芬片的药物组合物及其制备方法
CN111004165A (zh) * 2019-12-03 2020-04-14 南京正济医药研究有限公司 一种醋酸巴多昔芬晶型a的制备方法
CN112754999A (zh) * 2021-01-23 2021-05-07 郑州泰丰制药有限公司 一种醋酸巴多昔芬组合物及醋酸巴多昔芬薄膜衣片制备方法
CN113368075A (zh) * 2021-06-29 2021-09-10 郑州泰丰制药有限公司 一种醋酸巴多昔芬片及其制备方法
US20240350511A1 (en) * 2021-08-23 2024-10-24 Oxygen Biotech LLC Treatment of covid-19

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686094A (en) * 1991-04-01 1997-11-11 Theratech, Inc. Controlled release formulations for the treatment of xerostomia
HU223943B1 (hu) * 1995-06-22 2005-03-29 Akzo Nobel N.V. Dezogesztrelt tartalmazó, szárazon granulált, sajtolt tabletták és előállításuk
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
KR20030024659A (ko) 2000-02-17 2003-03-26 암겐 인코포레이티드 키나제 억제제
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
UA85374C2 (en) * 2002-06-13 2009-01-26 Уайт bazedoxifene treatment regimen
WO2005070434A2 (en) 2004-01-13 2005-08-04 Wyeth Treatment of aromatase inhibitor therapy-related osteoporosis
BRPI0509191A (pt) 2004-04-07 2007-09-25 Wyeth Corp polimorfo cristalino, composição, métodos de preparar forma a polimórfica de acetato de bazedoxifeno, de tratar um mamìfero possuindo uma doença ou sìndrome associada com deficiência de estrogênio ou excesso de estrogênio, e com proliferação ou desenvolvimento anormal de tecidos endometriais, cáncer de mama em um mamìfero, e uma mulher pós-menopausal para um ou vários distúrbios vasomotores, de abaixar colesterol em um mamìfero, e de inibir perda óssea em um mamìfero, e, forma a polimorfa cristalina de acetato de bazedoxifeno
CN1938272A (zh) * 2004-04-07 2007-03-28 惠氏公司 巴泽多昔芬醋酸盐的结晶多晶型物
EP1732889A1 (en) * 2004-04-07 2006-12-20 Wyeth Crystalline polymorph of bazedoxifene acetate
RU2400227C2 (ru) * 2004-04-08 2010-09-27 Вайет Состав, содержащий твердую дисперсию базедоксифен ацетата
BRPI0615341A2 (pt) * 2005-08-24 2011-05-17 Wyeth Corp composições farmacêuticas contendo acetato de bazedoxifeno, processo para preparação destas e comprimido ou cápsula contendo a referida composição

Also Published As

Publication number Publication date
RU2417084C2 (ru) 2011-04-27
IL189648A0 (en) 2008-08-07
US20070048374A1 (en) 2007-03-01
ZA200801742B (en) 2010-10-27
JP2013209419A (ja) 2013-10-10
CR9746A (es) 2008-08-21
BRPI0615341A2 (pt) 2011-05-17
AU2006283121A1 (en) 2007-03-01
NO20080991L (no) 2008-05-15
EP1919456A2 (en) 2008-05-14
KR20080043853A (ko) 2008-05-19
KR101584674B1 (ko) 2016-01-13
WO2007024961A3 (en) 2007-06-28
RU2008107580A (ru) 2009-09-27
TW200738281A (en) 2007-10-16
AR056471A1 (es) 2007-10-10
IL233392A0 (en) 2014-08-31
JP2009506053A (ja) 2009-02-12
CA2620174A1 (en) 2007-03-01
MX2008002484A (es) 2008-04-07
GT200600383A (es) 2007-03-29
US7771744B2 (en) 2010-08-10
WO2007024961A2 (en) 2007-03-01
PE20070425A1 (es) 2007-07-02
CN101304731A (zh) 2008-11-12
SV2008002825A (es) 2008-06-30
IL233392A (en) 2017-02-28
KR20140088917A (ko) 2014-07-11
CN101304731B (zh) 2012-06-20
IL189648A (en) 2014-07-31

Similar Documents

Publication Publication Date Title
ECSP088214A (es) Formulaciones de acetato de bazedoxifeno que tienen una conversión polimórfica reducida
ECSP066912A (es) Formulaciones de dispersiones sólidas de acetato de bazedoxifeno
IS8380A (is) Samsetningar með hátt innihald af alkóhóli sem líkjast hlaupi og eru freyðandi
DK2977061T3 (da) Fjernelse af peroxid fra vehikel til indgivelse af lægemiddel
ECSP066911A (es) Polimorfo cristalino de un acetato de bazedoxifeno
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
HN2008001103A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
ECSP066910A (es) Polimorfo cristalino de acetato de bazedoxifeno
ECSP11011139A (es) Anticuerpos contra la angiopoyetina 2 humana
NO20076687L (no) Oral doseringsform
EA201170703A1 (ru) Производные адамантилбензамида
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
BRPI0620229A8 (pt) formulação
EP2001400A4 (en) ORAL FORMULATIONS OF GLYCYL-2-METHYLPROLYL-GLUTAMATE
BRPI0907228A2 (pt) Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos
CL2007003593A1 (es) Composicion farmaceutica que comprende fluoresceina pura; procedimiento de preparacion de la fluoresceina.
DK1608344T3 (da) Orale cladribin-formuleringer
ITMI20051658A1 (it) Composizioni cosmetiche
CR10428A (es) 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzotiazepinas, su preparacion, composiciones que las contienen y utilizacion
ATE401864T1 (de) Orale flüssige citalopram enthaltende formulierungen
BRPI0508279A (pt) composições de peróxido estabilizadas
CR9435A (es) Uso de un compuesto
ITMI20050087A1 (it) Formulazioni orali contenenti propoli
CR8614A (es) Polimorfo cristalino de acetato de bazedoxifeno